2024 World Conference on Lung Cancer (WCLC) - Posters-P4.11E.17 Clinical Outcomes and Immunotherapy Retreatment in Patients with Metastatic NSCLC Who Complete at Least Two Years of Immune Checkpoint Blockade

P4.11E.17 Clinical Outcomes and Immunotherapy Retreatment in Patients with Metastatic NSCLC Who Complete at Least Two Years of Immune Checkpoint Blockade

Back to course

Pdf Summary

This document reports on a study investigating the long-term outcomes of patients with metastatic non-small cell lung cancer (NSCLC) who underwent at least two years of immune checkpoint inhibitor (ICI) therapy. It highlights how ICIs, with or without chemotherapy, have considerably enhanced survival rates, although the optimal duration for ICI treatment remains uncertain.<br /><br />The study analyzed data from 421 patients internationally across multiple centers, examining clinical outcomes and post-progression treatment patterns. Median progression-free survival (PFS) for patients who underwent a minimum of two years of ICI treatment was 5.7 years, while median overall survival (OS) was 9.5 years. Those who continued ICI treatment indefinitely demonstrated more favorable outcomes compared to those who stopped at two years. Specifically, patients on indefinite ICI had a median PFS of 6.8 years and an OS not yet reached, while those on fixed ICI had a median PFS of 5.2 years and OS of 7.6 years.<br /><br />A significant finding was that a considerable number of patients who experienced disease progression after initially completing two years of ICI therapy responded positively upon retreatment with additional ICIs, showing an objective response rate and improved survival outcomes. Median PFS and OS in this retreatment scenario were 22.7 months and 53.1 months, respectively.<br /><br />The patient cohort described was predominantly male (56.8%), with a high smoking history (91.6%) and had adenocarcinoma as the most common histology (78.9%). The study emphasizes that patients completing at least two years of ICI treatment demonstrated unprecedented long-term survival rates, and indefinite continuation of ICI may offer superior benefits compared to stopping treatment at two years. This investigation sheds light on the potential need to personalize the duration of ICI therapy in NSCLC patients.

Asset Subtitle

Biagio Ricciuti

Meta Tag

Speaker Biagio Ricciuti

Topic Metastatic NSCLC – Immunotherapy

Keywords

metastatic non-small cell lung cancer

immune checkpoint inhibitor therapy

long-term outcomes

progression-free survival

overall survival

retreatment

adenocarcinoma

personalized therapy

chemotherapy

survival rates